<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>LiquidMammo™ | Breast cancer screening, reimagined</title>

  <!-- SEO -->
  <meta name="description" content="LiquidMammo is a microRNA-based liquid biopsy for early breast cancer detection—non-invasive, clinician-ordered, and designed to complement imaging.">
  <meta name="keywords" content="breast cancer screening, microRNA test, liquid biopsy, early detection test, dense breasts screening, mammography complement, molecular breast cancer detection, microRNA breast cancer test, liquid biopsy breast cancer, LDT breast cancer test, non-invasive screening test, clinical decision support, molecular diagnostics, breast density screening, early-stage breast cancer detection">
  <meta name="theme-color" content="#E91E63">

  <!-- Stylesheet -->
  <link rel="stylesheet" href="assets/css/styles.css">

  <!-- Favicon -->
  <link rel="icon" href="favicon.png" type="image/png">

  <!-- Social (OpenGraph) -->
  <meta property="og:title" content="LiquidMammo™">
  <meta property="og:description" content="A microRNA-based liquid biopsy for early breast cancer detection.">
  <meta property="og:image" content="assets/logos/liquidmammo-logo.png">
  <meta property="og:type" content="website">
</head>

<body>

<header class="container">
  <nav style="display:flex;align-items:center;justify-content:space-between;gap:18px;">
    
    <!-- Brand -->
    <div class="brand" style="display:flex;align-items:center;gap:10px;">
      <img src="assets/logos/liquidmammo-logo.png" alt="LiquidMammo logo" style="height:34px;">
      <strong>LiquidMammo™</strong>
    </div>

    <!-- Navigation -->
    <div style="display:flex;gap:14px;flex-wrap:wrap;">
      <a href="how-it-works.html">How It Works</a>
      <a href="science.html">Science</a>
      <a href="evidence.html">Evidence</a>
      <a href="patients.html">Patients</a>
      <a href="clinicians.html">Clinicians</a>
      <a href="biobank.html">Biobank</a>
      <a href="pricing.html">Pricing</a>
      <a href="contact.html">Contact</a>
      <a href="privacy.html">Privacy</a>
    </div>

  </nav>
</header>

<!-- HERO -->
<section class="hero" style="padding:60px 0;background:#fff;">
  <div class="container" style="display:grid;gap:40px;grid-template-columns:1fr 1.1fr;align-items:center;">

    <!-- HERO TEXT -->
    <div>
      <h1 style="margin-bottom:12px;">Breast cancer screening, reimagined.</h1>

      <p class="kicker" style="margin-bottom:8px;">A microRNA blood test designed to complement imaging.</p>

      <p class="small" style="margin-bottom:16px;">
        Early molecular changes often precede structural findings on mammography. LiquidMammo provides a
        non‑invasive signal that strengthens clinical decision‑making—especially where breast density limits
        traditional imaging performance.
      </p>

      <div style="margin:16px 0;display:flex;gap:12px;">
        <a href="patients.html#join">Join Early Access</a>
        <a href="clinicians.html#enroll">Clinician Enrollment</a>
      </div>

      <p class="notice" style="margin-top:16px;">
        Regulatory: LiquidMammo is being developed as a <strong>CLIA Laboratory Developed Test (LDT)</strong>;
        not yet FDA‑cleared/approved.
      </p>
    </div>

    <!-- HERO IMAGE -->
    <div>
      <img src="https://images.unsplash.com/photo-1606205685561-2038323a6472?auto=format&fit=crop&w=1100&q=80"
           alt="Clinician handling blood tubes in a molecular diagnostics laboratory"
           style="width:100%;border-radius:12px;border:1px solid #e5e7eb;">
    </div>

  </div>
</section>

<!-- WHY IT MATTERS -->
<section class="panel-light section" style="padding:40px 0;">
  <div class="container grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr));gap:24px;">

    <div class="card-mini">
      <h4>Dense breasts challenge mammography</h4>
      <p class="small">Sensitivity drops to ~61% in extremely dense tissue. Interval cancers are more common. A molecular complement may reduce misses.</p>
    </div>

    <div class="card-mini">
      <h4>Earlier biological signal</h4>
      <p class="small">microRNA shifts can occur before imaging-visible lesions. Combining biology + imaging strengthens screening performance.</p>
    </div>

    <div class="card-mini">
      <h4>Addresses real-world variability</h4>
      <p class="small">Mammographic detection varies by density, age, equipment, and reader. A standardized molecular layer improves consistency.</p>
    </div>

  </div>
</section>

<!-- CLINICAL CONTEXT -->
<section class="container section" style="padding:40px 0;">
  <h2>Clinical context</h2>

  <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr));gap:24px;margin-top:20px;">
    
    <div class="card stats-card">
      <ul class="list-tight">
        <li><strong>1 in 8</strong> cancers missed by mammography overall</li>
        <li><strong>Higher interval cancer rates</strong> in dense breasts</li>
        <li><strong>~50–60%</strong> false‑positive probability over 10 years</li>
      </ul>
    </div>

    <div class="card stats-card">
      <ul class="list-tight">
        <li><strong>~61% sensitivity</strong> in extremely dense tissue</li>
        <li><strong>2–3 per 1,000</strong> cancers detected in younger women</li>
        <li><strong>Lower participation</strong> when imaging alone is used</li>
      </ul>
    </div>

  </div>
</section>

<!-- WORKFLOW -->
<section class="panel-light" style="padding:50px 0;">
  <div class="container">
    <h2>How it works</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr));gap:30px;margin-top:24px;">

      <div class="card-mini">
        <h4>1 — Ordered by clinician</h4>
        <p class="small">Clinician‑initiated blood draw at routine visit; no preparation needed.</p>
      </div>

      <div class="card-mini">
        <h4>2 — microRNA profiling</h4>
        <p class="small">A proprietary multi‑marker panel quantifies tumor‑associated microRNA dysregulation.</p>
      </div>

      <div class="card-mini">
        <h4>3 — Actionable report</h4>
        <p class="small">Results delivered to clinicians with density‑aware interpretation and subgroup context.</p>
      </div>

    </div>
  </div>
</section>

<!-- FOOTER -->
<footer>
  <div class="container footer-grid">
    
    <div>
      <strong>LiquidMammo™</strong><br>
      A test developed by MultiOmics Inc.
      <p class="footer-note">MultiOmics Inc. is headquartered in Washington, DC, and operates out of LabCentral, Cambridge, MA (MIT innovation ecosystem).</p>
    </div>

    <div class="footer-logo" style="justify-content:flex-end;text-align:right;">
      <img src="assets/logos/multiomics-logo.png" alt="MultiOmics logo" style="height:36px;">
      <div class="footer-note" style="line-height:1.2">Developed by<br>MultiOmics Inc.</div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    <a href="privacy.html">Privacy & Compliance</a> •
    <a href="contact.html">Order / Kits</a>
  </div>
</footer>

</body>
</html>





